Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 56

1.

Wiskott-Aldrich syndrome protein (WASP) is a tumor suppressor in T cell lymphoma.

Menotti M, Ambrogio C, Cheong TC, Pighi C, Mota I, Cassel SH, Compagno M, Wang Q, Dall'Olio R, Minero VG, Poggio T, Sharma GG, Patrucco E, Mastini C, Choudhari R, Pich A, Zamo A, Piva R, Giliani S, Mologni L, Collings CK, Kadoch C, Gambacorti-Passerini C, Notarangelo LD, Anton IM, Voena C, Chiarle R.

Nat Med. 2019 Jan;25(1):130-140. doi: 10.1038/s41591-018-0262-9. Epub 2018 Dec 3.

2.

Ground-glass nodules of the lung in never-smokers and smokers: clinical and genetic insights.

Kobayashi Y, Ambrogio C, Mitsudomi T.

Transl Lung Cancer Res. 2018 Aug;7(4):487-497. doi: 10.21037/tlcr.2018.07.04. Review.

3.

Impact of BRAF Mutation Class on Disease Characteristics and Clinical Outcomes in BRAF-mutant Lung Cancer.

Dagogo-Jack I, Martinez P, Yeap BY, Ambrogio C, Ferris LA, Lydon C, Nguyen T, Jessop NA, Iafrate AJ, Johnson BE, Lennerz JK, Shaw AT, Awad MM.

Clin Cancer Res. 2019 Jan 1;25(1):158-165. doi: 10.1158/1078-0432.CCR-18-2062. Epub 2018 Sep 17.

PMID:
30224342
4.

Assessing Therapeutic Efficacy of MEK Inhibition in a KRASG12C-Driven Mouse Model of Lung Cancer.

Li S, Liu S, Deng J, Akbay EA, Hai J, Ambrogio C, Zhang L, Zhou F, Jenkins RW, Adeegbe DO, Gao P, Wang X, Paweletz CP, Herter-Sprie GS, Chen T, Gutiérrez-Quiceno L, Zhang Y, Merlino AA, Quinn MM, Zeng Y, Yu X, Liu Y, Fan L, Aguirre AJ, Barbie DA, Yi X, Wong KK.

Clin Cancer Res. 2018 Oct 1;24(19):4854-4864. doi: 10.1158/1078-0432.CCR-17-3438. Epub 2018 Jun 26.

5.

An Acquired NRAS Q61K Mutation in BRAF V600E-Mutant Lung Adenocarcinoma Resistant to Dabrafenib Plus Trametinib.

Abravanel DL, Nishino M, Sholl LM, Ambrogio C, Awad MM.

J Thorac Oncol. 2018 Aug;13(8):e131-e133. doi: 10.1016/j.jtho.2018.03.026. Epub 2018 Apr 6. No abstract available.

6.

A putative role for Discoidin Domain Receptor 1 in cancer chemoresistance.

Ambrogio C, Darbo E, Lee SW, Santamaría D.

Cell Adh Migr. 2018;12(4):394-397. doi: 10.1080/19336918.2018.1445954. Epub 2018 Apr 3. Review.

7.

KRAS Dimerization Impacts MEK Inhibitor Sensitivity and Oncogenic Activity of Mutant KRAS.

Ambrogio C, Köhler J, Zhou ZW, Wang H, Paranal R, Li J, Capelletti M, Caffarra C, Li S, Lv Q, Gondi S, Hunter JC, Lu J, Chiarle R, Santamaría D, Westover KD, Jänne PA.

Cell. 2018 Feb 8;172(4):857-868.e15. doi: 10.1016/j.cell.2017.12.020. Epub 2018 Jan 11.

8.

A Braf kinase-inactive mutant induces lung adenocarcinoma.

Nieto P, Ambrogio C, Esteban-Burgos L, Gómez-López G, Blasco MT, Yao Z, Marais R, Rosen N, Chiarle R, Pisano DG, Barbacid M, Santamaría D.

Nature. 2017 Aug 10;548(7666):239-243. doi: 10.1038/nature23297. Epub 2017 Aug 2.

9.

Potent and Selective Covalent Quinazoline Inhibitors of KRAS G12C.

Zeng M, Lu J, Li L, Feru F, Quan C, Gero TW, Ficarro SB, Xiong Y, Ambrogio C, Paranal RM, Catalano M, Shao J, Wong KK, Marto JA, Fischer ES, Jänne PA, Scott DA, Westover KD, Gray NS.

Cell Chem Biol. 2017 Aug 17;24(8):1005-1016.e3. doi: 10.1016/j.chembiol.2017.06.017. Epub 2017 Aug 3.

10.

Back to the Bench? MEK and ERK Inhibitors for the Treatment of KRAS Mutant Lung Adenocarcinoma.

Kohler J, Catalano M, Ambrogio C.

Curr Med Chem. 2018 Feb 13;25(5):558-574. doi: 10.2174/0929867324666170530093100. Review.

PMID:
28554329
11.

Phosphatidylinositol 3-kinase δ blockade increases genomic instability in B cells.

Compagno M, Wang Q, Pighi C, Cheong TC, Meng FL, Poggio T, Yeap LS, Karaca E, Blasco RB, Langellotto F, Ambrogio C, Voena C, Wiestner A, Kasar SN, Brown JR, Sun J, Wu CJ, Gostissa M, Alt FW, Chiarle R.

Nature. 2017 Feb 23;542(7642):489-493. doi: 10.1038/nature21406. Epub 2017 Feb 15.

12.

KRAS-driven lung adenocarcinoma: combined DDR1/Notch inhibition as an effective therapy.

Ambrogio C, Nadal E, Villanueva A, Gómez-López G, Cash TP, Barbacid M, Santamaría D.

ESMO Open. 2016 Sep 6;1(5):e000076. eCollection 2016. Review.

13.

In vivo oncogenic conflict triggered by co-existing KRAS and EGFR activating mutations in lung adenocarcinoma.

Ambrogio C, Barbacid M, Santamaría D.

Oncogene. 2017 Apr 20;36(16):2309-2318. doi: 10.1038/onc.2016.385. Epub 2016 Oct 24.

PMID:
27775074
14.

Combined inhibition of DDR1 and Notch signaling is a therapeutic strategy for KRAS-driven lung adenocarcinoma.

Ambrogio C, Gómez-López G, Falcone M, Vidal A, Nadal E, Crosetto N, Blasco RB, Fernández-Marcos PJ, Sánchez-Céspedes M, Ren X, Wang Z, Ding K, Hidalgo M, Serrano M, Villanueva A, Santamaría D, Barbacid M.

Nat Med. 2016 Mar;22(3):270-7. doi: 10.1038/nm.4041. Epub 2016 Feb 8.

PMID:
26855149
15.

Redundant and nonredundant roles for Cdc42 and Rac1 in lymphomas developed in NPM-ALK transgenic mice.

Choudhari R, Minero VG, Menotti M, Pulito R, Brakebusch C, Compagno M, Voena C, Ambrogio C, Chiarle R.

Blood. 2016 Mar 10;127(10):1297-306. doi: 10.1182/blood-2015-11-683052. Epub 2016 Jan 8.

16.

Excess of NPM-ALK oncogenic signaling promotes cellular apoptosis and drug dependency.

Ceccon M, Merlo MEB, Mologni L, Poggio T, Varesio LM, Menotti M, Bombelli S, Rigolio R, Manazza AD, Di Giacomo F, Ambrogio C, Giudici G, Casati C, Mastini C, Compagno M, Turner SD, Gambacorti-Passerini C, Chiarle R, Voena C.

Oncogene. 2016 Jul 21;35(29):3854-3865. doi: 10.1038/onc.2015.456. Epub 2015 Dec 14.

17.

Efficacy of a Cancer Vaccine against ALK-Rearranged Lung Tumors.

Voena C, Menotti M, Mastini C, Di Giacomo F, Longo DL, Castella B, Merlo MEB, Ambrogio C, Wang Q, Minero VG, Poggio T, Martinengo C, D'Amico L, Panizza E, Mologni L, Cavallo F, Altruda F, Butaney M, Capelletti M, Inghirami G, Jänne PA, Chiarle R.

Cancer Immunol Res. 2015 Dec;3(12):1333-1343. doi: 10.1158/2326-6066.CIR-15-0089. Epub 2015 Sep 29.

18.

Therapeutic inhibition of TRF1 impairs the growth of p53-deficient K-RasG12V-induced lung cancer by induction of telomeric DNA damage.

García-Beccaria M, Martínez P, Méndez-Pertuz M, Martínez S, Blanco-Aparicio C, Cañamero M, Mulero F, Ambrogio C, Flores JM, Megias D, Barbacid M, Pastor J, Blasco MA.

EMBO Mol Med. 2015 Jul;7(7):930-49. doi: 10.15252/emmm.201404497.

19.

Increased Rrm2 gene dosage reduces fragile site breakage and prolongs survival of ATR mutant mice.

Lopez-Contreras AJ, Specks J, Barlow JH, Ambrogio C, Desler C, Vikingsson S, Rodrigo-Perez S, Green H, Rasmussen LJ, Murga M, Nussenzweig A, Fernandez-Capetillo O.

Genes Dev. 2015 Apr 1;29(7):690-5. doi: 10.1101/gad.256958.114.

20.

Simple and rapid in vivo generation of chromosomal rearrangements using CRISPR/Cas9 technology.

Blasco RB, Karaca E, Ambrogio C, Cheong TC, Karayol E, Minero VG, Voena C, Chiarle R.

Cell Rep. 2014 Nov 20;9(4):1219-27. doi: 10.1016/j.celrep.2014.10.051. Epub 2014 Nov 13.

21.

Lentiviral-based approach for the validation of cancer therapeutic targets in vivo.

Ambrogio C, Stern P, Scuoppo C, Kranz H, Barbacid M, Santamaría D.

Biotechniques. 2014 Oct 1;57(4):179, 181-7. doi: 10.2144/000114214. eCollection 2014 Oct.

22.

Modeling lung cancer evolution and preclinical response by orthotopic mouse allografts.

Ambrogio C, Carmona FJ, Vidal A, Falcone M, Nieto P, Romero OA, Puertas S, Vizoso M, Nadal E, Poggio T, Sánchez-Céspedes M, Esteller M, Mulero F, Voena C, Chiarle R, Barbacid M, Santamaría D, Villanueva A.

Cancer Res. 2014 Nov 1;74(21):5978-88. doi: 10.1158/0008-5472.CAN-14-1606. Epub 2014 Sep 12.

23.

ALK-dependent control of hypoxia-inducible factors mediates tumor growth and metastasis.

Martinengo C, Poggio T, Menotti M, Scalzo MS, Mastini C, Ambrogio C, Pellegrino E, Riera L, Piva R, Ribatti D, Pastorino F, Perri P, Ponzoni M, Wang Q, Voena C, Chiarle R.

Cancer Res. 2014 Nov 1;74(21):6094-106. doi: 10.1158/0008-5472.CAN-14-0268. Epub 2014 Sep 5.

24.

Epigenetic silencing of the proapoptotic gene BIM in anaplastic large cell lymphoma through an MeCP2/SIN3a deacetylating complex.

Piazza R, Magistroni V, Mogavero A, Andreoni F, Ambrogio C, Chiarle R, Mologni L, Bachmann PS, Lock RB, Collini P, Pelosi G, Gambacorti-Passerini C.

Neoplasia. 2013 May;15(5):511-22.

25.

The EGFR family members sustain the neoplastic phenotype of ALK+ lung adenocarcinoma via EGR1.

Voena C, Di Giacomo F, Panizza E, D'Amico L, Boccalatte FE, Pellegrino E, Todaro M, Recupero D, Tabbò F, Ambrogio C, Martinengo C, Bonello L, Pulito R, Hamm J, Chiarle R, Cheng M, Ruggeri B, Medico E, Inghirami G.

Oncogenesis. 2013 Apr 8;2:e43. doi: 10.1038/oncsis.2013.7.

26.

PPP4R2 regulates neuronal cell differentiation and survival, functionally cooperating with SMN.

Bosio Y, Berto G, Camera P, Bianchi F, Ambrogio C, Claus P, Di Cunto F.

Eur J Cell Biol. 2012 Aug;91(8):662-74. doi: 10.1016/j.ejcb.2012.03.002. Epub 2012 May 3.

PMID:
22559936
27.

Selective therapeutic targeting of the anaplastic lymphoma kinase with liposomal siRNA induces apoptosis and inhibits angiogenesis in neuroblastoma.

Di Paolo D, Ambrogio C, Pastorino F, Brignole C, Martinengo C, Carosio R, Loi M, Pagnan G, Emionite L, Cilli M, Ribatti D, Allen TM, Chiarle R, Ponzoni M, Perri P.

Mol Ther. 2011 Dec;19(12):2201-12. doi: 10.1038/mt.2011.142. Epub 2011 Aug 9.

28.

Expression of IFNγR2 mutated in a dileucine internalization motif reinstates IFNγ signaling and apoptosis in human T lymphocytes.

Boselli D, Ragimbeau J, Orlando L, Cappello P, Capello M, Ambrogio C, Chiarle R, Marsili G, Battistini A, Giovarelli M, Pellegrini S, Novelli F.

Immunol Lett. 2010 Nov 30;134(1):17-25. doi: 10.1016/j.imlet.2010.08.005. Epub 2010 Aug 13.

PMID:
20709103
29.

Involvement of Grb2 adaptor protein in nucleophosmin-anaplastic lymphoma kinase (NPM-ALK)-mediated signaling and anaplastic large cell lymphoma growth.

Riera L, Lasorsa E, Ambrogio C, Surrenti N, Voena C, Chiarle R.

J Biol Chem. 2010 Aug 20;285(34):26441-50. doi: 10.1074/jbc.M110.116327. Epub 2010 Jun 16.

30.

MT1-MMP is required for myeloid cell fusion via regulation of Rac1 signaling.

Gonzalo P, Guadamillas MC, Hernández-Riquer MV, Pollán A, Grande-García A, Bartolomé RA, Vasanji A, Ambrogio C, Chiarle R, Teixidó J, Risteli J, Apte SS, del Pozo MA, Arroyo AG.

Dev Cell. 2010 Jan 19;18(1):77-89. doi: 10.1016/j.devcel.2009.11.012.

31.

NPM-ALK oncogenic tyrosine kinase controls T-cell identity by transcriptional regulation and epigenetic silencing in lymphoma cells.

Ambrogio C, Martinengo C, Voena C, Tondat F, Riera L, di Celle PF, Inghirami G, Chiarle R.

Cancer Res. 2009 Nov 15;69(22):8611-9. doi: 10.1158/0008-5472.CAN-09-2655. Epub 2009 Nov 3.

32.

Leukocyte transmigration is modulated by chemokine-mediated PI3Kgamma-dependent phosphorylation of vimentin.

Barberis L, Pasquali C, Bertschy-Meier D, Cuccurullo A, Costa C, Ambrogio C, Vilbois F, Chiarle R, Wymann M, Altruda F, Rommel C, Hirsch E.

Eur J Immunol. 2009 Apr;39(4):1136-46. doi: 10.1002/eji.200838884.

33.

Assessment of sleep in ventilator-supported critically III patients.

Ambrogio C, Koebnick J, Quan SF, Ranieri M, Parthasarathy S.

Sleep. 2008 Nov;31(11):1559-68.

34.

The anaplastic lymphoma kinase controls cell shape and growth of anaplastic large cell lymphoma through Cdc42 activation.

Ambrogio C, Voena C, Manazza AD, Martinengo C, Costa C, Kirchhausen T, Hirsch E, Inghirami G, Chiarle R.

Cancer Res. 2008 Nov 1;68(21):8899-907. doi: 10.1158/0008-5472.CAN-08-2568.

35.

Human Wrnip1 is localized in replication factories in a ubiquitin-binding zinc finger-dependent manner.

Crosetto N, Bienko M, Hibbert RG, Perica T, Ambrogio C, Kensche T, Hofmann K, Sixma TK, Dikic I.

J Biol Chem. 2008 Dec 12;283(50):35173-85. doi: 10.1074/jbc.M803219200. Epub 2008 Oct 7.

36.

Sleep and non-invasive ventilation in patients with chronic respiratory insufficiency.

Ambrogio C, Lowman X, Kuo M, Malo J, Prasad AR, Parthasarathy S.

Intensive Care Med. 2009 Feb;35(2):306-13. doi: 10.1007/s00134-008-1276-4. Epub 2008 Sep 16.

PMID:
18795255
37.

The anaplastic lymphoma kinase is an effective oncoantigen for lymphoma vaccination.

Chiarle R, Martinengo C, Mastini C, Ambrogio C, D'Escamard V, Forni G, Inghirami G.

Nat Med. 2008 Jun;14(6):676-80. doi: 10.1038/nm1769. Epub 2008 May 11.

PMID:
18469826
38.

The anaplastic lymphoma kinase in the pathogenesis of cancer.

Chiarle R, Voena C, Ambrogio C, Piva R, Inghirami G.

Nat Rev Cancer. 2008 Jan;8(1):11-23. Review.

PMID:
18097461
39.

Polysomnography during critical illness.

Ambrogio C, Parthasarathy S.

J Clin Sleep Med. 2007 Oct 15;3(6):649-50. No abstract available.

40.

Negative feedback regulation of Rac in leukocytes from mice expressing a constitutively active phosphatidylinositol 3-kinase gamma.

Costa C, Barberis L, Ambrogio C, Manazza AD, Patrucco E, Azzolino O, Neilsen PO, Ciraolo E, Altruda F, Prestwich GD, Chiarle R, Wymann M, Ridley A, Hirsch E.

Proc Natl Acad Sci U S A. 2007 Sep 4;104(36):14354-9. Epub 2007 Aug 24.

41.

The Down syndrome critical region protein TTC3 inhibits neuronal differentiation via RhoA and Citron kinase.

Berto G, Camera P, Fusco C, Imarisio S, Ambrogio C, Chiarle R, Silengo L, Di Cunto F.

J Cell Sci. 2007 Jun 1;120(Pt 11):1859-67. Epub 2007 May 8.

42.

The tyrosine phosphatase Shp2 interacts with NPM-ALK and regulates anaplastic lymphoma cell growth and migration.

Voena C, Conte C, Ambrogio C, Boeri Erba E, Boccalatte F, Mohammed S, Jensen ON, Palestro G, Inghirami G, Chiarle R.

Cancer Res. 2007 May 1;67(9):4278-86. Erratum in: Cancer Res. 2016 Mar 15;76(6):1669.

43.

Patient-ventilator interaction and sleep in mechanically ventilated patients: pressure support versus proportional assist ventilation.

Bosma K, Ferreyra G, Ambrogio C, Pasero D, Mirabella L, Braghiroli A, Appendini L, Mascia L, Ranieri VM.

Crit Care Med. 2007 Apr;35(4):1048-54.

PMID:
17334259
44.

Ablation of oncogenic ALK is a viable therapeutic approach for anaplastic large-cell lymphomas.

Piva R, Chiarle R, Manazza AD, Taulli R, Simmons W, Ambrogio C, D'Escamard V, Pellegrino E, Ponzetto C, Palestro G, Inghirami G.

Blood. 2006 Jan 15;107(2):689-97. Epub 2005 Sep 27.

45.

p130Cas mediates the transforming properties of the anaplastic lymphoma kinase.

Ambrogio C, Voena C, Manazza AD, Piva R, Riera L, Barberis L, Costa C, Tarone G, Defilippi P, Hirsch E, Boeri Erba E, Mohammed S, Jensen ON, Palestro G, Inghirami G, Chiarle R.

Blood. 2005 Dec 1;106(12):3907-16. Epub 2005 Aug 16. Erratum in: Blood. 2009 Sep 24;114(13):2851.

46.

Preliminary results of an investigation on the possible interaction of alpha-MSH and CRH in the regulation of gonadotropin secretion.

Limone P, Scipioni T, Calvelli P, Scaglione E, Ambrogio C, Boeri E, Barberis AM, Molinatti GM.

Ann N Y Acad Sci. 1993 May 31;680:561-3. No abstract available.

PMID:
8390193
47.

Stimulatory effect of the adrenergic system on alpha-MSH secretion in man. Role of beta-receptors.

Limone P, D'Alessandro V, Rainero I, Ambrogio C, Boeri E, De Gennaro T, Molinatti GM.

Ann N Y Acad Sci. 1993 May 31;680:558-60. No abstract available.

PMID:
8390192
48.

Adrenergic regulation of alpha-MSH secretion in man: evidence for a stimulatory role of beta-receptors.

Limone P, D'Alessandro V, Rainero I, Ambrogio C, Pinessi L, De Gennaro T, Molinatti GM.

Acta Endocrinol (Copenh). 1993 Feb;128(2):150-5.

PMID:
8383904
49.

Clonidine lowers alpha-MSH-like immunoreactivity in human plasma.

Limone P, D'Alessandro V, Rainero I, De Gennaro T, Ambrogio C, Fulgido G, Pinessi L, Molinatti GM.

Life Sci. 1993;53(22):1703-8.

PMID:
8231651
50.

Role of adhesive proteins in platelet tumor interaction in vitro and metastasis formation in vivo.

Karpatkin S, Pearlstein E, Ambrogio C, Coller BS.

J Clin Invest. 1988 Apr;81(4):1012-9.

Supplemental Content

Loading ...
Support Center